다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of controlled release : official journal of the Controlled Release Society, v.247, 2017년, pp.28 - 54
Botella, Pablo (Corresponding author.) , Rivero-Buceta, Eva
AI-Helper
Abstract Twenty-(S)-camptothecin is a strongly cytotoxic molecule with excellent antitumor activity over a wide spectrum of human cancers. However, the direct formulation is limited by its poor water solubility, low plasmatic stability and severe toxicity, which currently limits its clinical use. A...
J. Am. Chem. Soc. Wall 88 3888 1966 10.1021/ja00968a057 Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
Cancer Res. Beidler 56 345 1996 Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines
Cancer Res. Giovanella 51 3052 1991 Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin
Cancer Res. Del Bino 50 5746 1990 Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells
Cancer Res. Li 32 2643 1972 Action of camptothecin on mammalian cells in culture
Annu. Rev. Pharmacol. Toxicol. Chen 34 191 1994 10.1146/annurev.pa.34.040194.001203 DNA topoisomerases: essential enzymes and lethal targets
J. Nat. Prod. Oberlies 67 129 2004 10.1021/np030498t Camptothecin and taxol: historic achievements in natural products research
Anti-Cancer Drugs Clements 7 851 1996 10.1097/00001813-199611000-00006 Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro
Heteroat. Chem. Liu 22 687 2011 10.1002/hc.20734 Synthesis and insecticidal activities of novel spin-labeled derivatives of camptothecin
PLoS One Zhang 8 2013 Characterization of DNA topoisomerase-1 in Spodoptera exigua for toxicity evaluation of camptothecin and hydroxycamptothecin
Int. J. Dermatol. Lin 27 475 1988 10.1111/j.1365-4362.1988.tb00923.x Topical camptothecine in treatment of psoriasis
Chin. Med. J. Chiao 1 355 1975 Effect of topical use of camptothecine-dimethyl sulfoxide solution in psoriasis
Proc. Natl. Acad. Sci. U. S. A. Bodley 92 3726 1995 10.1073/pnas.92.9.3726 Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania
Antimicrob. Agents Chemother. del Poeta 43 2862 1999 10.1128/AAC.43.12.2862 Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells
Phosphorus Sulfur Alaghaz 187 799 2012 10.1080/10426507.2011.631643 Synthesis, spectroscopic, and antimicrobial activity studies of novel 10-substituted camptothecin phosphorothioate analogs
Molecules Li 15 138 2009 10.3390/molecules15010138 The anti-HIV actions of 7- and 10-substituted camptothecins
Antimicrob. Agents Chemother. Horwitz 2 395 1972 10.1128/AAC.2.5.395 Antiviral action of camptothecin
Ann. N. Y. Acad. Sci. Boven 922 175 2000 10.1111/j.1749-6632.2000.tb07035.x New analogues of camptothecins. Activity and resistance
J. Biol. Chem. Hsiang 260 14873 1985 10.1016/S0021-9258(17)38654-4 Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
Drug Des. Rev. Online Tobin 1 341 2004 10.2174/1567269043390573 Camptothecins and key lessons in drug design
J. Appl. Pharmacol. Muqeet 6 286 2014 Camptothecin and its analogs antitumor activity by poisoning topoisomerase I, their structure activity relationship and clinical development perspective of analogs
Clin. Cancer Res. Garcia-Carbonero 8 641 2002 Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins
J. Comput. Aided Mol. Des. Carrigan 11 71 1997 10.1023/A:1008027528218 Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents
Biochemistry Zihou 33 10325 1994 10.1021/bi00200a013 Differential interactions of camptothecin lactone and carboxylate forms with human blood components
Expert Opin. Ther. Pat. Basili 19 555 2009 10.1517/13543770902773437 Novel camptothecin derivatives as topoisomerase I inhibitors
Pharm. Res. Hatefi 19 1389 2002 10.1023/A:1020427227285 Camptothecin delivery methods
J. Chem. Eng. Data Zhi 61 2052 2016 10.1021/acs.jced.5b00994 Measurement and correlation of the solubility for camptothecine in different organic solvents
Expert Opin. Investig. Drugs Zunino 13 269 2004 10.1517/13543784.13.3.269 Camptothecins in clinical development
Cancer Res. Kunimoto 47 5944 1987 Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water soluble derivative of camptothecin, against murine tumors
Med. Res. Rev. Liu 35 753 2015 10.1002/med.21342 Perspectives on biologically active camptothecin derivatives
Pharm. Res. Hanson 20 1031 2003 10.1023/A:1024410322870 A mechanistic and kinetic study of the E-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin
Arch. Pharm. Xu 347 240 2013 10.1002/ardp.201300177 Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug
Chem. Biodivers. Müller 6 2071 2009 10.1002/cbdv.200900114 Prodrug approaches for enhancing the bioavailability of drugs with low solubility
Bioorg. Med. Chem. Thomas 12 1585 2004 10.1016/j.bmc.2003.11.036 Camptothecin: current perspectives
Chem. Rev. Verma 109 213 2009 10.1021/cr0780210 Camptothecins: a SAR/QSAR study
Mol. Pharm. Venditto 7 307 2010 10.1021/mp900243b Cancer therapies utilizing the camptothecins: a review of the in vivo literature
J. Med. Chem. Hertzberg 32 715 1989 10.1021/jm00123a038 Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity
Bioorg. Med. Chem. Srivastava 13 5892 2005 10.1016/j.bmc.2005.05.066 Plant-based anticancer molecules: a chemical and biological profile of some important leads
Bioorg. Med. Chem. Lett. Wang 18 4095 2008 10.1016/j.bmcl.2008.05.103 Novel hexacyclic camptothecin derivatives. Part 1: synthesis and cytotoxicity of camptothecins with an A-ring fused 1, 3-oxazine ring
Biochem. Pharmacol. de Cesare 73 656 2007 10.1016/j.bcp.2006.11.004 Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series
Bioorg. Med. Chem. Lett. Jiao 21 2071 2011 10.1016/j.bmcl.2011.02.005 Synthesis and antitumor activity of 10-arylcamptothecin derivatives
Bioorg. Med. Chem. Lett. Dallavalle 18 2781 2008 10.1016/j.bmcl.2008.04.016 Synthesis and cytotoxic activity of new 9-substituted camptothecins
Chin. Chem. Lett. Xiao 20 566 2009 10.1016/j.cclet.2008.12.019 Synthesis and cytotoxic activity of 7-alkynyl camptothecin derivatives
J. Med. Chem. Wani 29 2358 1986 10.1021/jm00161a035 Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues
ACS Med. Chem. Lett. Rodriguez-Berna 4 651 2013 10.1021/ml400125z Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives
J. Med. Chem. Wall 36 2689 1993 10.1021/jm00070a013 Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs
Cancer Res. Emerson 55 603 1995 In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues
J. Med. Chem. Sugimori 37 3033 1994 10.1021/jm00045a007 Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues
J. Med. Chem. Burke 36 2580 1993 10.1021/jm00069a020 Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin
J. Chromatogr. B Anal. Technol. Biomed. Life Sci. Yu 951-952 62 2014 10.1016/j.jchromb.2014.01.017 Development and validation of a sensitive LC-MS/MS method for simultaneous quantification of sinotecan and its active metabolite in human blood
Nat. Prod. Res. Sriram 19 393 2005 10.1080/14786410412331299005 Camptothecin and its analogues: a review on their chemotherapeutic potential
Bioorg. Med. Chem. Lett. Subrahmanyam 9 1633 1999 10.1016/S0960-894X(99)00268-1 Novel C ring analogues of 20(S)-camptothecin. Part-2: synthesis and in vitro cytotoxicity of 5-C-substituted 20(S)-camptothecin analogues
J. Med. Chem. Duan 54 1715 2011 10.1021/jm101354u 14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment
J. Clin. Pharmacol. Chatterjee 44 723 2004 10.1177/0091270004265647 Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study
Bioorg. Med. Chem. Wang 12 3657 2004 10.1016/j.bmc.2004.04.023 Synthesis and antitumor activity of 20-O-linked nitrogen-based camptothecin ester derivatives
J. Am. Chem. Soc. Hu 135 17617 2013 10.1021/ja409686x Polyprodrug amphiphiles: hierarchical assemblies for shape-regulated cellular internalization, trafficking, and drug delivery
J. Mater. Chem. B Lin 1 6147 2013 10.1039/c3tb20867b Preparation, characterization, and in vitro evaluation of folate-modified mesoporous bioactive glass for targeted anticancer drug carriers
ACS Appl. Mater. Interfaces Ha 6 10623 2014 10.1021/am5022864 Tunable temperature-responsive supramolecular hydrogels formed by prodrugs as a codelivery system
Eur. J. Med. Chem. Huang 63 746 2013 10.1016/j.ejmech.2013.01.058 Evolution in medicinal chemistry of E-ring-modified camptothecin analogs as anticancer agents
Eur. J. Cancer Bleiberg 35 371 1999 10.1016/S0959-8049(98)00423-7 CPT-11 in gastrointestinal cancer
Cancer Res. Kawato 51 4187 1991 Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
Pharm. Res. Tian 22 1837 2005 10.1007/s11095-005-7595-z Human multidrug resistance associated protein 4 confers resistance to camptothecins
J. Control. Release Bala 172 48 2013 10.1016/j.jconrel.2013.07.022 Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38
J. Clin. Oncol. Creemers 14 3056 1996 10.1200/JCO.1996.14.12.3056 Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study
Cancer Res. Pantazis 53 1577 1993 Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro
Expert Opin. Investig. Drugs Clark 15 71 2006 10.1517/13543784.15.1.71 Rubitecan
Oncologist Burris 3 183 2005 10.1634/theoncologist.10-3-183 Phase II trial of oral rubitecan in previously treated pancreatic cancer patients
Cancer Res. Treat. Jung 38 159 2006 10.4143/crt.2006.38.3.159 The synergism between belotecan and cisplatin in gastric cancer
Lung Cancer Lim 80 313 2013 10.1016/j.lungcan.2013.02.009 Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer
Clin. Cancer Res. Garrison 9 2527 2003 Phase I and pharmacokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
Br. J. Cancer Gerrits 76 946 1997 10.1038/bjc.1997.490 The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor
Int. Res. J. Pharm. Ranjit 4 47 2013 Nanoparticle: an overview of preparation, characterization and application
Lancet Gabizon 384 2175 2014 10.1016/S0140-6736(14)61457-4 Cancer nanomedicines: closing the translational gap
J. Phys. D. Appl. Phys. Re 45 073001 2012 10.1088/0022-3727/45/7/073001 Nanoparticles for neuroimaging
Adv. Funct. Mater. Doshi 19 3843 2009 10.1002/adfm.200901538 Designer biomaterials for nanomedicine
J. Nanobiotechnol. Mahapatro 9 55 2011 10.1186/1477-3155-9-55 Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
J. Am. Chem. Soc. Shen 132 4259 2010 10.1021/ja909475m Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery
Chem. Ind. Duncan 7 262 1997 Polymer therapeutics for tumor specific delivery
Adv. Drug Deliv. Rev. Venditto 65 80 2013 10.1016/j.addr.2012.09.038 Cancer nanomedicines: so many papers and so few drugs!
Adv. Drug Deliv. Rev. Torchilin 58 1532 2006 10.1016/j.addr.2006.09.009 Multifunctional nanocarriers
Curr. Opin. Pharmacol. López-Dávila 12 414 2012 10.1016/j.coph.2012.02.011 Organic nanocarriers for cancer drug delivery
J. Mater. Sci. Eng. Dikmen 5 468 2011 Advantage and disadvantage in drug delivery systems
Adv. Drug Deliv. Rev. Matsumura 63 184 2011 10.1016/j.addr.2010.05.008 Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect
Mutat. Res. Jeetah 768 47 2014 10.1016/j.mrfmmm.2014.04.009 Polymeric nanomicelles for sustained delivery of anti-cancer drugs
Nanoscale Liu 8 3510 2016 10.1039/C5NR08345A Distinct CPT-induced deaths in lung cancer cells caused by clathrin-mediated internalization of CP micelles
Cancer Sci. Matsumura 100 572 2009 10.1111/j.1349-7006.2009.01103.x Preclinical and clinical studies of anticancer agent-incorporating polymer micelles
Pharm. Res. Opanasopit 21 2001 2004 10.1023/B:PHAM.0000048190.53439.eb Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting
J. Drug Target. Yokoyama 12 373 2004 10.1080/10611860412331285251 Polymer design and incorporation methods for polymeric micelle carrier system containing water-insoluble anti-cancer agent camptothecin
Int. J. Pharm. Watanabe 308 183 2006 10.1016/j.ijpharm.2005.10.030 Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability
Colloids Surf., B Fan 75 543 2010 10.1016/j.colsurfb.2009.09.034 Fabrication of nanomicelle with enhanced solubility and stability of camptothecin based on α,β-poly[(N-carboxybutyl)-L-aspartamide]-camptothecin conjugate
Colloids Surf., B Zhang 81 297 2010 10.1016/j.colsurfb.2010.07.019 Nanomicelle with long-term circulation and enhanced stability of camptothecin based on mPEGylated α,β-poly(L-aspartic acid)-camptothecin conjugate
ACS Nano Yen 8 11591 2014 10.1021/nn504836s Light-induced cytosolic activation of reduction-sensitive camptothecin-loaded polymeric micelles for spatiotemporally controlled in vivo chemotherapy
Pharm. Sci. Technol. Today Emerson 3 205 2000 10.1016/S1461-5347(00)00268-6 Liposomal delivery of camptothecins
AAPS PharmSciTech Sætern 5 2004 10.1208/pt050340 A method to determine the incorporation capacity of camptothecin in liposomes
Cancer Chemother. Pharmacol. Sugarman 37 531 1996 10.1007/s002800050425 Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies
J. Control. Release Watanabe 127 231 2008 10.1016/j.jconrel.2008.02.005 In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin
Mol. Pharm. Duncan 8 2101 2011 10.1021/mp200394t Nanomedicine(s) under the microscope
Eur. J. Med. Chem. Cheng 43 1791 2008 10.1016/j.ejmech.2007.09.030 Potential of poly(amidoamine) dendrimers as drug carriers of camptothecin based on encapsulation studies
Adv. Drug Deliv. Rev. Lim 15 826 2012 10.1016/j.addr.2012.03.008 Triazine dendrimers as drug delivery systems: from synthesis to therapy
Bioconjug. Chem. Gopin 17 1432 2006 10.1021/bc060180n Enzymatic activation of second-generation dendritic prodrugs: conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry
Chem. Commun. Venditto 5541 2009 10.1039/b911353c Intercepting the synthesis of triazine dendrimers with nucleophilic pharmacophores: a general strategy toward drug delivery vehicles
RSC Adv. Zolotarskaya 5 58600 2015 10.1039/C5RA07987J Click synthesis of a polyamidoamine dendrimer-based camptothecin prodrug
J. Polym. Sci. A Polym. Chem. Feng 49 2839 2011 10.1002/pola.24718 Sequential functionalization of janus-type dendrimer-like poly(ethylene oxide)s with camptothecin and folic acid
J. Bioact. Compat. Polym. Seymour 6 178 1991 10.1177/088391159100600205 Review: synthetic polymers with intrinsic anticancer activity
Nat. Rev. Drug Discov. Duncan 2 347 2003 10.1038/nrd1088 The dawning era of polymer therapeutics
Kunugi 2012 Nanomedicine Polymers
Angew. Chem. Int. Ed. Haag 45 1198 2006 10.1002/anie.200502113 Polymer therapeutics: concepts and applications
Sun 245 2013 10.1039/9781849737388-00245 RSC Polymer Chemistry Series Functional polymers for nanomedicine. polymer-based prodrugs for cancer chemotherapy
Acta Biomater. Chen 43 195 2016 10.1016/j.actbio.2016.07.020 Tunable conjugation densities of camptothecin on hyaluronic acid for tumor targeting and reduction-triggered release
Trends Biotechnol. Vicent 24 39 2006 10.1016/j.tibtech.2005.11.006 Polymer conjugates: nanosized medicines for treating cancer
Annu. Rev. Chem. Biomol. Eng. Liechty 1 149 2010 10.1146/annurev-chembioeng-073009-100847 Polymers for drug delivery systems
Polymer Duro-Castano 6 515 2014 10.3390/polym6020515 Peptide-based polymer therapeutics
J. Am. Chem. Soc. Cai 137 3458 2015 10.1021/ja513034e Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency
Bioconjug. Chem. Cheng 14 1007 2003 10.1021/bc0340924 Synthesis of linear, β-cyclodextrin-based polymers and their camptothecin conjugates
Mol. Pharm. Cheng 1 183 2004 10.1021/mp049966y Antitumor activity of β-cyclodextrin polymer-camptothecin conjugates
Proc. Natl. Acad. Sci. U. S. A. Schluep 106 11394 2009 10.1073/pnas.0905487106 Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements
Adv. Drug Deliv. Rev. Davis 61 1189 2009 10.1016/j.addr.2009.05.005 Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin
Clin. Cancer Res. Schluep 12 1606 2006 10.1158/1078-0432.CCR-05-1566 Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models
Cancer Chemother. Pharmacol. Schluep 57 654 2006 10.1007/s00280-005-0091-7 Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice
Colloids Surf., B Zeng 105 120 2013 10.1016/j.colsurfb.2012.12.024 Hollow nanosphere fabricated from β-cyclodextrin-grafted α,β-poly(aspartic acid) as the carrier of camptothecin
Eur. J. Pharm. Sci. Minelli 47 686 2012 10.1016/j.ejps.2012.08.003 Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells
Int. J. Oncol. Zou 18 331 2001 Effectiveness of water soluble poly(L-glutamic acid)camptothecin conjugate against resistant human lung cancer xenografted in nude mice
J. Control. Release Singer 74 243 2001 10.1016/S0168-3659(01)00323-6 Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo
Int. J. PharmTech. Res. Kumar 6 433 2014 Enhanced activity of camptothecin hydrogel by using HP-β-cyclodextrin
J. Control. Release Min 127 208 2008 10.1016/j.jconrel.2008.01.013 Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy
ACS Nano Soukasene 5 9113 2011 10.1021/nn203343z Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin
J. Control. Release Huang 155 344 2011 10.1016/j.jconrel.2011.06.004 Inorganic nanoparticles for cancer imaging and therapy
Mater. Today Giner-Casares 19 19 2016 10.1016/j.mattod.2015.07.004 Inorganic nanoparticles for biomedicine: where materials scientists meet medical research
Adv. Drug Deliv. Rev. Nam 65 622 2013 10.1016/j.addr.2012.08.015 Surface engineering of inorganic nanoparticles for imaging and therapy
Dalton Trans. Zhu 43 7275 2014 10.1039/C3DT53493F Uniform iron oxide hollow spheres for high-performance delivery of insoluble anticancer drugs
Beilstein J. Nanotechnol. Castillo 5 1312 2014 10.3762/bjnano.5.144 PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
Curr. Opin. Chem. Biol. Bianco 9 674 2005 10.1016/j.cbpa.2005.10.005 Applications of carbon nanotubes in drug delivery
Chem. Commun. Sahoo 47 5235 2011 10.1039/c1cc00075f Functionalized carbon nanomaterials as nanocarriers for loading and delivery of a poorly water-soluble anticancer drug: a comparative study
ACS Nano Assali 7 2145 2013 10.1021/nn304986x Glyconanosomes: disk-shaped nanomaterials for the water solubilization and delivery of hydrophobic molecules
Kickelbick 516 2007 Hybrid Materials: Synthesis, Characterization, and Applications
Mater. Today Fahmi 12 44 2009 10.1016/S1369-7021(09)70159-2 Functional hybrid materials
Small Li 12 4782 2016 10.1002/smll.201601129 Recent advances of using hybrid nanocarriers in remotely controlled therapeutic delivery
Angew. Chem. Int. Ed. Vallet-Regí 46 7548 2007 10.1002/anie.200604488 Mesoporous materials for drug delivery
Small Lu 3 1341 2007 10.1002/smll.200700005 Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs
Small Lu 6 1794 2010 10.1002/smll.201000538 Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals
Nanomed. Nanotechnol. Biol. Med. Lu 8 212 2012 10.1016/j.nano.2011.06.002 In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification
J. Mater. Chem. Ma 22 5615 2012 10.1039/c2jm15489g Hyaluronic acid-conjugated mesoporous silica nanoparticles: excellent colloidal dispersity in physiological fluids and targeting efficacy
Nature Asefa 402 867 1999 10.1038/47229 Periodic mesoporous organosilicas with organic groups inside the channel walls
J. Am. Chem. Soc. Inagaki 121 9611 1999 10.1021/ja9916658 Novel mesoporous materials with a uniform distribution of organic groups and inorganic oxide in their frameworks
Chem. Mater. Melde 11 3302 1999 10.1021/cm9903935 Mesoporous sieves with unified hybrid inorganic/organic frameworks
Adv. Mater. Chen 28 3235 2016 10.1002/adma.201505147 Chemistry of mesoporous organosilica in nanotechnology: molecularly organic-inorganic hybridization into frameworks
J. Am. Chem. Soc. Chen 136 16326 2014 10.1021/ja508721y Hollow mesoporous organosilica nanoparticles: a generic intelligent framework-hybridization approach for biomedicine
J. Am. Chem. Soc. Lu 134 8746 2012 10.1021/ja301691j Multifluorescent traceable nanoparticle by a single-wavelength excitation with color-related drug release performance
Angew. Chem. Int. Ed. Yan 43 5980 2004 10.1002/anie.200460598 Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities
Carbohydr. Polym. Hsiao 89 632 2012 10.1016/j.carbpol.2012.03.066 Nano-hybrid carboxymethyl chitosan modified with (3-aminopropyl)triethoxysilane for camptothecin delivery
J. Control. Release Tyner 95 501 2004 10.1016/j.jconrel.2003.12.027 Nanobiohybrids as delivery vehicles for camptothecin
Nanoscale Schärtl 2 829 2010 10.1039/c0nr00028k Current directions in core-shell nanoparticle design
J. Nanopart. Res. Ünal 17 42 2015 10.1007/s11051-014-2838-8 Core-shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation
ACS Appl. Mater. Interfaces Chen 4 5766 2012 10.1021/am301223n Gold nanocluster-conjugated amphiphilic block copolymer for tumor-targeted drug delivery
Dalton Trans. Botella 41 9286 2012 10.1039/c2dt30381g Multifunctional hybrid materials for combined photo and chemotherapy of cancer
Langmuir Xu 30 7789 2014 10.1021/la500595b tLyP-1-conjugated Au-nanorod@SiO2 core-shell nanoparticles for tumor targeted drug delivery and photothermal therapy
Angew. Chem. Int. Ed. Horcajada 45 5974 2006 10.1002/anie.200601878 Metal-organic frameworks as efficient materials for drug delivery
Acc. Chem. Res. Rocca 44 957 2011 10.1021/ar200028a Nanoscale metal-organic frameworks for biomedical imaging and drug delivery
Coord. Chem. Rev. Giménez-Marqués 307 342 2016 10.1016/j.ccr.2015.08.008 Nanostructured metal-organic frameworks and their bio-related applications
ACS Nano Zhuang 8 2812 2014 10.1021/nn406590q Optimized metal-organic-framework nanospheres for drug delivery: evaluation of small-molecule encapsulation
Mater. Lett. Ji 59 682 2005 10.1016/j.matlet.2004.11.008 Solvothermal synthesis and thermoelectric properties of lanthanum contained Bi-Te and Bi-Se-Te alloys
J. Control. Release Ganta 126 187 2008 10.1016/j.jconrel.2007.12.017 A review of stimuli-responsive nanocarriers for drug and gene delivery
Nat. Mater. Mura 12 991 2013 10.1038/nmat3776 Stimuli-responsive nanocarriers for drug delivery
Adv. Drug Deliv. Rev. Fleige 64 866 2012 10.1016/j.addr.2012.01.020 Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications
Chem. Soc. Rev. Tong 43 6982 2014 10.1039/C4CS00133H Smart chemistry in polymeric nanomedicine
Biomaterials Kanamala 85 152 2016 10.1016/j.biomaterials.2016.01.061 Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review
J. Control. Release Min 144 259 2010 10.1016/j.jconrel.2010.02.024 Tumoral acidic pH-responsive MPEG-poly(β-amino ester) polymeric micelles for cancer targeting therapy
Bioconjug. Chem. Han 24 669 2013 10.1021/bc300640j Targeted nanoparticles assembled via complexation of boronic-acid-containing targeting moieties to diol-containing polymers
Nanotechnology Tang 24 145101 2013 10.1088/0957-4484/24/14/145101 A pH-responsive chitosan-b-poly(p-dioxanone) nanocarrier: formation and efficient antitumor drug delivery
RSC Adv. Li 5 77097 2015 10.1039/C5RA15728E A pH-sensitive nanocarrier for co-delivery of doxorubicin and camptothecin to enhance chemotherapeutic efficacy and overcome multidrug resistance in vitro
Cell Biochem. Funct. Balendiran 22 343 2004 10.1002/cbf.1149 The role of glutathione in cancer
Biomacromolecules Wang 14 3706 2013 10.1021/bm401086d Redox responsive, core-cross-linked micelles capable of on-demand, concurrent drug release and structure disassembly
RSC Adv. Muniesa 3 15121 2013 10.1039/c3ra41404c Glutathione-sensitive nanoplatform for monitored intracellular delivery and controlled release of camptothecin
Mater. Sci. Eng. C Botella 58 692 2016 10.1016/j.msec.2015.09.012 Effect of drug precursor in cell uptake and cytotoxicity of redox-responsive camptothecin nanomedicines
J. Am. Chem. Soc. Cheetman 135 2907 2013 10.1021/ja3115983 Supramolecular nanostructures formed by anticancer drug assembly
Chem. Commun. Cheetham 50 6039 2014 10.1039/C3CC49453E Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles
ACS Nano Lin 8 12690 2014 10.1021/nn505688b Multiwalled nanotubes formed by catanionic mixtures of drug amphiphiles
Adv. Drug Deliv. Rev. Rica 64 967 2012 10.1016/j.addr.2012.01.002 Enzyme-responsive nanoparticles for drug release and diagnostics
J. Control. Release Botella 156 246 2011 10.1016/j.jconrel.2011.06.039 Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation
Biomaterials Chen 33 1162 2012 10.1016/j.biomaterials.2011.10.044 The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles
Pharm. Res. Thiagarajan 27 2307 2010 10.1007/s11095-010-0179-6 PAMAM-camptothecin conjugate inhibits proliferation and induces nuclear fragmentation in colorectal carcinoma cell
Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. Tong 4 638 2012 10.1002/wnan.1188 Shedding light on nanomedicine
Acc. Chem. Res. Bansal 47 3052 2014 10.1021/ar500217w Photocontrolled nanoparticle delivery systems for biomedical applications
Angew. Chem. Int. Ed. Croissant 52 13813 2013 10.1002/anie.201308647 Two-photon-triggered drug delivery in cancer cells using nanoimpellers
Small Lu 4 421 2008 10.1002/smll.200700903 Light-activated nanoimpeller-controlled drug release in cancer cells
J. Am. Chem. Soc. Tan 137 6112 2015 10.1021/jacs.5b00795 Light-triggered, self-immolative nucleic acid-drug nanostructures
ACS Nano Chen 8 744 2014 10.1021/nn405398d A light-responsive release platform by controlling the wetting behavior of hydrophobic surface
Curr. Opin. Colloid Interface Bonini 18 459 2013 10.1016/j.cocis.2013.07.007 Nanostructures for magnetically triggered release of drugs and biomolecules
Angew. Chem. Int. Ed. Giri 44 5038 2005 10.1002/anie.200501819 Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles
J. Mater. Chem. Chen 21 2535 2011 10.1039/c0jm02590a Multifunctional magnetically removable nanogated lids of Fe3O4-capped mesoporous silica nanoparticles for intracellular controlled release and MR imaging
Acta Biomater. Tung 7 2873 2011 10.1016/j.actbio.2011.03.021 Synthesis of nanocarriers with remote magnetic drug release control and enhanced drug delivery for intracellular targeting of cancer cells
Langmuir Hu 24 239 2008 10.1021/la701570z Magnetic-sensitive silica nanospheres for controlled drug release
Acta Biomater. Kong 9 5447 2013 10.1016/j.actbio.2012.11.006 Magnetic field activated lipid-polymer hybrid nanoparticles for stimuli-responsive drug release
J. Control. Release Jhaveri 190 352 2014 10.1016/j.jconrel.2014.05.002 Stimuli-sensitive nanopreparations for combination cancer therapy
Colloids Surf., B Luo 114 150 2014 10.1016/j.colsurfb.2013.09.043 Thermosensitive PNIPAM-b-HTPB block copolymer micelles: molecular architectures and camptothecin drug release
Ultrasonics Fang 49 39 2009 10.1016/j.ultras.2008.04.009 Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells
Adv. Drug Deliv. Rev. Unger 56 1291 2004 10.1016/j.addr.2003.12.006 Therapeutic applications of lipid-coated microbubbles
Polym. Chem. Ma 5 1503 2014 10.1039/C3PY01202F Phenylboronic acid-based glucose-responsive polymeric nanoparticles: synthesis and applications in drug delivery
ACS Appl. Mater. Interfaces Sinha 6 22183 2014 10.1021/am505848p Dextran-gated, multifunctional mesoporous nanoparticle for glucose-responsive and targeted drug delivery
J. Control. Release Svenson 153 49 2011 10.1016/j.jconrel.2011.03.007 Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101
Nat. Rev. Mater. Wilhelm 1 16014 2016 10.1038/natrevmats.2016.14 Analysis of nanoparticle delivery to tumours
WIREs Nanomed. Nanobiotechnol. Svenson 6 125 2014 10.1002/wnan.1257 What nanomedicine in the clinic right now really forms nanoparticles?
Investig. New Drugs Weiss 4 986 2013 10.1007/s10637-012-9921-8 First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Proc. Natl. Acad. Sci. U. S. A. Eliasof 110 15127 2013 10.1073/pnas.1309566110 Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticles
Proc. Natl. Acad. Sci. U. S. A. Clark 113 3850 2016 10.1073/pnas.1603018113 CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing
Ann. N. Y. Acad. Sci. Singer 902 136 2000 Conjugation of camptothecins to poly-(l-glutamic acid)
J. Clin. Oncol. Springett 22 3127 2004 10.1200/jco.2004.22.14_suppl.3127 Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies
Clin. Cancer Res. Homsi 13 5855 2007 10.1158/1078-0432.CCR-06-2821 Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
Adv. Drug Deliv. Rev. Yurkovetskiy 61 1193 2009 10.1016/j.addr.2009.01.007 XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer
Clin. Cancer Res. Walsh 18 2591 2012 10.1158/1078-0432.CCR-11-1554 Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts
Mol. Cancer Ther. Sausville 6 A146 2007 A phase I study of the safety, tolerability, and pharmacokinetics of intravenous XMT-1001 in patients with advanced solid tumors
Crit. Rev. Ther. Drug Greenwald 17 101 2000 10.1615/CritRevTherDrugCarrierSyst.v17.i2.20 Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review
J. Clin. Oncol. Rowinsky 21 148 2003 10.1200/JCO.2003.03.143 A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3weeks in patients with advanced solid malignancies
J. Clin. Oncol. Scott 22 2004 10.1200/jco.2004.22.14_suppl.4030 Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: preliminary results of a single-agent phase 2 study
Cancer Chemother. Pharmacol. Scott 63 363 2009 10.1007/s00280-008-0746-2 A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
Adv. Drug Deliv. Rev. Duncan 61 1131 2009 10.1016/j.addr.2009.05.007 Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt
Cancer Chemother. Pharmacol. Conover 42 407 1998 10.1007/s002800050837 Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker
Br. J. Cancer Schoemaker 87 608 2002 10.1038/sj.bjc.6600516 A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
Br. J. Cancer Bissett 91 50 2004 10.1038/sj.bjc.6601922 Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.